


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

X is C<sub>1-6</sub> alkylene or C<sub>2-6</sub> alkenylene, each of which is optionally substituted by one or more fluorine atoms;

R is aryl or C<sub>3-8</sub> cycloalkyl optionally substituted by one or more fluorine atoms;

W is N or CZ;

Y is

(a) NR<sup>1</sup>R<sup>3</sup>,

(b) C<sub>1-4</sub> alkyl substituted by NR<sup>1</sup>R<sup>2</sup> or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is

optionally substituted by one or more substituents independently selected from  $R^2$ , =O and OH,

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from  $R^2$ , =O and OH,

Z is H or  $C_{1-4}$  alkyl,

or when W is CZ, Y can be H or  $C_{1-4}$  alkyl, and Z can be

(a)  $NR^1R^3$ ,

(b)  $C_{1-4}$  alkyl substituted by  $NR^1R^2$  or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from  $R^2$ , =O and OH,

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from  $R^2$ , =O and OH,

$R^2$  is H,

$C_{1-6}$  alkyl (optionally substituted by one or more substituents independently selected from OH,  $C_{1-4}$  alkoxy,  $C(O)_p(C_{1-4}$  alkyl, aryl, heteroaryl, or  $NR^1R^3$ ),  $CONR^1R^3$  or  $NR^1R^3$ ),

$SO_2(C_{1-4}$  alkyl, aryl, heteroaryl or  $NR^1R^3$ ),

$C(O)_p(C_{1-4}$  alkyl optionally substituted by  $C_{1-4}$  alkoxy or  $NR^1R^3$ ),

$C(O)_p(C_{3-7}$  cycloalkyl),

$C(O)_p(\text{aryl})$ ,

$C(O)_p(\text{heteroaryl})$ ,

$CONR^1R^3$ ,

$C_{3-7}$  cycloalkyl optionally substituted by one or more substituents independently selected from OH and  $C_{1-4}$  alkoxy,

a 4- to 7-membered saturated or partially or fully unsaturated heterocycle, which heterocycle ring contains up to 3 ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from  $R^3$ , =O, OH,  $SO_2(C_{1-4} \text{ alkyl})$  and/or  $C(O)_p(C_{1-4} \text{ alkyl})$  groups, or aryl,

$R^1$  and  $R^3$  are each independently selected from H and ( $C_{1-4}$  alkyl optionally substituted by OH,  $NR^4R^5$  or by  $C_{1-4}$  alkoxy),

$R^4$  and  $R^5$  are each independently selected from H and  $C_{1-4}$  alkyl,


p is 1 or 2,

"aryl" is phenyl optionally substituted by one or more substituents independently selected from  $R^3$ , OH,  $SO_2(C_{1-4} \text{ alkyl})$  and/or  $C(O)_p(C_{1-4} \text{ alkyl})$  groups,

"heteroaryl" is a 5- to 7-membered aromatic heterocycle with 1, 2 or 3 ring hetero-atoms independently selected from N, O and S, and which ring is optionally substituted by one or more substituents independently selected from  $R^3$ , =O, OH,  $SO_2(C_{1-4} \text{ alkyl})$  and/or  $C(O)_p(C_{1-4} \text{ alkyl})$  groups,

or a and the pharmaceutically acceptable salts, solvates (including hydrates) or and prodrugs thereof.

Claim 2 (original): A compound, salt, solvate or prodrug according to claim 1 wherein the compound of formula (I) has the following stereochemistry (IA):



Claim 3 (original): A compound, salt, solvate or prodrug according to claim 1 wherein W is N.

Claim 4 (original): A compound, salt, solvate or prodrug according to claim 1 wherein X is a linear C<sub>2-6</sub> alkylene moiety optionally substituted by one or more fluorine atoms.

Claim 5 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is C<sub>3-8</sub> cycloalkyl optionally substituted by one or more fluorine atoms.

Claim 6 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is C<sub>1-4</sub> alkyl substituted by NR<sup>1</sup>R<sup>2</sup>, or Y is a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R<sup>2</sup>, =O and OH.

Claim 7 (original): A compound, salt, solvate or prodrug according to claim 1 wherein W is CZ and Z is H or CH<sub>3</sub>.

Claim 8 (original): A compound, salt, solvate or prodrug according to claim 1 wherein X is propylene.

Claim 9 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclobutyl, cyclopentyl or cyclohexyl optionally substituted by one or more fluorine atoms.

Claim 10 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH<sub>2</sub> substituted by NR<sup>1</sup>R<sup>2</sup>, or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by one or more substituents independently selected from R<sup>2</sup>, =O and OH.

Claim 11 (original): A compound, salt, solvate or prodrug according to claim 1 wherein R is cyclohexyl.

Claim 12 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH<sub>2</sub>N(H or CH<sub>3</sub>)(SO<sub>2</sub>(C<sub>1-4</sub> alkyl, aryl, heteroaryl or NR<sup>1</sup>R<sup>3</sup>)), or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by SO<sub>2</sub>(C<sub>1-4</sub> alkyl) and/or C(O)<sub>p</sub>(C<sub>1-4</sub> alkyl) groups.

Claim 13 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is CH<sub>2</sub>NHSO<sub>2</sub>(C<sub>1-4</sub> alkyl), or Y is a 6-membered saturated N-heterocycle, and which heterocycle is optionally substituted by SO<sub>2</sub>(C<sub>1-4</sub> alkyl) or C(O)<sub>p</sub>(C<sub>1-4</sub> alkyl).

Claim 14 (original): A compound, salt, solvate or prodrug according to claim 1 wherein Y is  $\text{CH}_2\text{NHSO}_2\text{CH}_3$  or methylsulphonylpiperidinyl.

Claim 15 (original): A compound selected from any of the Examples disclosed herein, or a salt, solvate or prodrug thereof.

Claim 16 (original): A pharmaceutical composition comprising a compound, salt, solvate or prodrug according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 17 (original): A kit comprising :  
a compound, salt, solvate or prodrug according to claim 1, packaging; and  
instructions for the use of the said compound, salt, solvate, prodrug or  
composition in a manner suitable for treating or preventing a condition mediated  
by PCP.

Claim 18 (original): A compound, salt, solvate or prodrug according to of claim 1 for use in treating or preventing a condition mediated by PCP.

Claim 19 (original): A method of treating or preventing a condition mediated by PCP which comprises administration of an effective amount of a compound, salt, solvate or prodrug according to claim 1 to a patient in need thereof.